Canadian research: Hashish use in sufferers with head and neck most cancers not related to creating a second major most cancers

Article content continued

The study was conducted by researchers from McMaster University, the University of British Columbia, and the University of Toronto and considered the results of 513 patients, 59 of them in the cannabis group and 454 in the control group.

All patients were from the Hamilton Region Head and Neck Cancer Database and were treated at a single cancer center between 2011 and 2015.

There was no significant difference between patients in the cannabis and control groups, “except that cannabis users were more likely to develop primary oropharyngeal cancer,” the abstract says.

Two of the 59 patients who used cannabis, 3.4 percent, developed a second primary cancer compared to 23 of the 454 patients, 5.1 percent of the controls. Both the cannabis users and six of the controls who developed an SPC were active cigarette smokers, the study says. “Eleven of the 17 non-cigarette smokers who developed an SPC were ex-cigarette smokers.”

Two of the 59 patients who used cannabis, 3.4 percent, developed a second primary cancer. /. Photo by Getty Images

However, recognizing the limitations of the study, the authors write: “Our results are consistent with the theory that cannabis is not carcinogenic and therefore does not follow any pattern of field cancer. Instead, it is hypothesized that risk behavior associated with cannabis use may be linked to HNC through the effects of an HPV-positive disease (human papillomavirus) rather than a real carcinogen. “

The study results released by the University of California’s San Diego School of Medicine in early 2020 showed how researchers believe cannabis accelerates the growth of HPV-related HNC. “HPV-related head and neck cancer is one of the fastest growing cancers in the United States. At the same time, exposure to marijuana accelerates. This is a major public health problem, ”said professor and lead study author Dr. Joseph Califano III.

Another study, published this time in 2015, found “no association between lifelong marijuana use and head and neck cancer development”. When it was found that approximately 12.6 percent of the cases and 14.3 percent of the controls in the study were using cannabis, “the meta-analysis found no association between exposure and disease”.

In the Canadian study, cannabis use in HNC patients was found to be 11.4 percent. The researchers suggest that getting a better picture of cannabis smoking and the risk of SPC can help health care providers.

“While our study confirms the theory that recreational cannabis is a non-carcinogenic entity, further research would be beneficial to examine the risk of cannabis use in SPC so that healthcare providers can advise patients accurately on the risk of cannabis use after HNC treatment” the study adds.

Comments are closed.